ArticleJournal of applied clinical medical physics2026
Proton stereotactic body radiotherapy for early-stage non-small cell lung cancer: Influence of case-specific characteristics on dosimetric robustness.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Proton stereotactic body radiotherapy for early-stage non-small cell lung cancer: Influence of case-specific characteristics on dosimetric robustness.Journal of applied clinical medical physics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
background and purposeProton stereotactic body radiotherapy (SBRT) offers superior dose conformity. However, its clinical application remains limited due to uncertainties from setup errors and respiratory motion. This study quantified the dosimetric robustness of proton SBRT for early-stage non-small cell lung cancer under combined setup and interplay uncertainties and investigated the association between dosimetric robustness and case-specific characteristics.
methodsRobust proton SBRT plans were generated considering setup and range uncertainties. Dosimetric robustness was evaluated by comparing the clinical target volume (CTV) coverage indices (V95%, V98%, and V100%) between the nominal condition and conditions incorporating combined setup and interplay uncertainties. The influence of respiratory amplitude, tumor volume, and mean tumor CT value on dosimetric robustness was assessed.
resultsCTV coverage remained stable under nominal conditions. However, dose degradation occurred under combined setup and interplay uncertainties, with the median CTV V100% decreased below 70%. Larger respiratory amplitudes and lower mean tumor CT values were associated with reduced dosimetric robustness.
conclusionsCombined uncertainties significantly affected the dosimetric robustness of proton SBRT depending on case-specific characteristics. Our exploratory analysis indicates the potential need for individualized robustness strategies in proton SBRT planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.